References
- Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology 2008;47(11):1686–91.
- Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010;22(5):561–6.
- Henter JI, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, et al.; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.
- Parodi A, Davì S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, et al.; Lupus Working Group of the Paediatric Rheumatology European Society. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60(11):3388–99.
- Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology 2010;40:1285–92.
- Durand M, Troyanov Y, Laflamme P, Gregoire G: Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010;37(4):879–80.
- Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17(1):23–7.
- Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007;166:95–109.
- Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(3):965–71.
- Kim JM, Kwok SK, Ju JH, Park KS, Park GS, Kim HY, Park SH. Macrophage activation syndrome resistant to medical therapy in a patient with systemic lupus erythematosus and its remission with splenectomy. Rheumatol Int. 2013;33(3):767–71.
- Sproat LO, Pantanowitz L, Lu CM, Dezube BJ. Human immunodeficiency virus-associated hemophagocytosis with iron-deficiency anemia and massive splenomegaly. Clin Infect Dis. 2003;37:e170–3
- Ross CW, Schnitzer B, Weston BW, Hanson CA. Chronic active Epstein-Barr virus infection and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med. 1991;115(5):470–4
- Sellmer A, Stausbøl-Grøn B, Krag-Olsen B, Herlin T. Successful use of infliximab in macrophage activation syndrome with severe CNS involvement. Scand J Rheumatol. 2011;40(2):156–7. Epub 2010 Sep 26.
- Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30(2):401–3.
- Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21(1):92–6.